Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLFS NASDAQ:ESTA NASDAQ:RXST NASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLFSBioLife Solutions$20.81-2.1%$22.00$19.10▼$29.55$995.21M1.76389,948 shs394,039 shsESTAEstablishment Labs$41.34-1.5%$40.41$26.56▼$50.85$1.21B0.83303,225 shs316,182 shsRXSTRxSight$7.80+0.3%$11.91$6.32▼$58.23$316.16M1.162.13 million shs947,863 shsTNDMTandem Diabetes Care$15.40-1.2%$18.30$14.31▼$47.60$1.04B1.481.65 million shs1.39 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLFSBioLife Solutions-2.12%-7.84%-8.53%-17.65%-13.36%ESTAEstablishment Labs-1.48%-2.52%-6.81%+23.81%-6.98%RXSTRxSight+0.26%-2.13%-40.64%-50.79%-82.96%TNDMTandem Diabetes Care-1.16%-3.08%-9.84%-28.31%-58.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLFSBioLife Solutions2.7847 of 5 stars3.53.00.00.02.12.50.6ESTAEstablishment Labs1.8434 of 5 stars3.40.00.00.01.92.50.6RXSTRxSight3.3549 of 5 stars4.04.00.00.02.81.70.6TNDMTandem Diabetes Care3.5899 of 5 stars3.21.00.04.93.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLFSBioLife Solutions 3.00Buy$31.0048.97% UpsideESTAEstablishment Labs 2.83Moderate Buy$54.8332.64% UpsideRXSTRxSight 1.91Reduce$17.50124.36% UpsideTNDMTandem Diabetes Care 2.36Hold$32.71112.43% UpsideCurrent Analyst Ratings BreakdownLatest RXST, ESTA, BLFS, and TNDM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025BLFSBioLife SolutionsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$30.007/16/2025ESTAEstablishment LabsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$58.00 ➝ $70.007/15/2025RXSTRxSightMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$20.00 ➝ $9.007/10/2025RXSTRxSightJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$24.00 ➝ $9.007/9/2025ESTAEstablishment LabsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$38.00 ➝ $47.007/9/2025RXSTRxSightBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderperform ➝ Underperform$18.00 ➝ $9.007/9/2025RXSTRxSightPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$18.00 ➝ $10.007/9/2025RXSTRxSightStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$17.00 ➝ $9.007/9/2025RXSTRxSightOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform7/9/2025RXSTRxSightWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$25.00 ➝ $9.007/9/2025RXSTRxSightNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLFSBioLife Solutions$87.76M11.34$0.12 per share173.53$7.52 per share2.77ESTAEstablishment Labs$166.02M7.20N/AN/A$1.90 per share21.76RXSTRxSight$139.93M2.27N/AN/A$6.98 per share1.12TNDMTandem Diabetes Care$982.95M1.04N/AN/A$4.01 per share3.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLFSBioLife Solutions-$20.18M-$0.29N/AN/AN/A-11.81%-0.66%-0.58%8/7/2025 (Estimated)ESTAEstablishment Labs-$84.60M-$3.10N/AN/AN/A-52.34%-196.25%-26.64%8/7/2025 (Estimated)RXSTRxSight-$27.45M-$0.67N/AN/AN/A-17.90%-9.54%-8.51%8/7/2025 (Estimated)TNDMTandem Diabetes Care-$96.03M-$2.78N/AN/AN/A-18.71%-57.33%-13.48%8/6/2025 (Confirmed)Latest RXST, ESTA, BLFS, and TNDM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025BLFSBioLife Solutions-$0.02N/AN/AN/A$23.71 millionN/A8/7/2025Q2 2025ESTAEstablishment Labs-$0.54N/AN/AN/A$50.80 millionN/A8/7/2025Guidance UpdateRXSTRxSight-$0.0363N/AN/AN/A$39.78 millionN/A8/6/2025Q2 2025TNDMTandem Diabetes Care-$0.40N/AN/AN/A$238.39 millionN/A5/8/2025Q1 2025BLFSBioLife Solutions-$0.03$0.04+$0.07-$0.01$22.22 million$23.94 million5/7/2025Q1 2025ESTAEstablishment Labs-$0.83-$0.70+$0.13-$0.70$41.15 million$41.38 million5/7/2025Q1 2025RXSTRxSight-$0.03-$0.03N/A-$0.20$38.74 million$37.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLFSBioLife SolutionsN/AN/AN/AN/AN/AESTAEstablishment LabsN/AN/AN/AN/AN/ARXSTRxSightN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLFSBioLife Solutions0.014.733.74ESTAEstablishment Labs5.723.362.05RXSTRxSightN/A12.6811.65TNDMTandem Diabetes Care1.992.301.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLFSBioLife Solutions93.24%ESTAEstablishment Labs72.91%RXSTRxSight78.78%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipBLFSBioLife Solutions2.20%ESTAEstablishment Labs11.09%RXSTRxSight9.57%TNDMTandem Diabetes Care1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLFSBioLife Solutions44047.84 million46.78 millionOptionableESTAEstablishment Labs1,01828.92 million25.71 millionOptionableRXSTRxSight22040.64 million36.75 millionOptionableTNDMTandem Diabetes Care2,65066.61 million65.34 millionOptionableRXST, ESTA, BLFS, and TNDM HeadlinesRecent News About These CompaniesTandem Diabetes Care, Inc. (NASDAQ:TNDM) Position Increased by Bayforest Capital LtdAugust 1 at 5:53 AM | marketbeat.comTandem Diabetes Care Announces Upcoming Conference ParticipationJuly 31 at 4:05 PM | businesswire.com1 of Wall Street’s Favorite Stock to Research Further and 2 Facing HeadwindsJuly 31 at 3:48 PM | finance.yahoo.comTandem Diabetes Care (TNDM) Expected to Announce Earnings on WednesdayJuly 31 at 7:06 AM | marketbeat.comTandem Diabetes Care, Inc. (TNDM) Expected to Beat Earnings Estimates: Should You Buy?July 30 at 11:06 AM | zacks.comTandem Diabetes Care (NASDAQ:TNDM) Stock Price Up 5.8% - Here's What HappenedJuly 29, 2025 | marketbeat.comGSA Capital Partners LLP Takes $2.50 Million Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)July 29, 2025 | marketbeat.comWhy Tandem Diabetes (TNDM) Stock Is Trading Up TodayJuly 28, 2025 | msn.comTandem Diabetes Care issues insulin pump warning over potential speaker malfunctionJuly 26, 2025 | massdevice.com1492 Capital Management LLC Makes New $430,000 Investment in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)July 24, 2025 | marketbeat.comEnvestnet Asset Management Inc. Buys 64,467 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)July 24, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Purchased by Cerity Partners LLCJuly 22, 2025 | marketbeat.comTandem Diabetes Care (NASDAQ:TNDM) Hits New 12-Month Low - Time to Sell?July 21, 2025 | marketbeat.comDown 27.0% in 4 Weeks, Here's Why You Should You Buy the Dip in Tandem Diabetes Care (TNDM)July 21, 2025 | zacks.comGW&K Investment Management LLC Purchases 740,499 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)July 21, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Rating of "Hold" by AnalystsJuly 20, 2025 | marketbeat.comHussman Strategic Advisors Inc. Makes New $1.21 Million Investment in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)July 19, 2025 | marketbeat.comTandem Diabetes Care's SWOT analysis: stock faces headwinds amid market shiftsJuly 17, 2025 | investing.comWhat is Leerink Partnrs' Estimate for TNDM FY2025 Earnings?July 16, 2025 | marketbeat.comTandem Diabetes Care (NASDAQ:TNDM) Hits New 52-Week Low - Here's What HappenedJuly 15, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Bought by Stephens Investment Management Group LLCJuly 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesChipotle: Too Spicy for Smart Money to Resist After Stock SplitBy Jeffrey Neal Johnson | July 11, 2025View Chipotle: Too Spicy for Smart Money to Resist After Stock SplitIs China Investable Again? 2 Stocks Soaring as Tensions EaseBy Dan Schmidt | July 21, 2025View Is China Investable Again? 2 Stocks Soaring as Tensions EaseWhy Prologis May Be the Smartest Backdoor Bet on AI Real EstateBy Chris Markoch | July 17, 2025View Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate3 Fast Food Stocks That Won’t Give You Indigestion Right NowBy Brian O'Connell | July 16, 2025View 3 Fast Food Stocks That Won’t Give You Indigestion Right NowHow Texas Roadhouse Is Winning in a Changing Consumer MarketBy Dan Schmidt | July 14, 2025View How Texas Roadhouse Is Winning in a Changing Consumer MarketRXST, ESTA, BLFS, and TNDM Company DescriptionsBioLife Solutions NASDAQ:BLFS$20.81 -0.45 (-2.12%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$20.80 0.00 (-0.02%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.Establishment Labs NASDAQ:ESTA$41.34 -0.62 (-1.48%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$41.01 -0.33 (-0.80%) As of 08/1/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.RxSight NASDAQ:RXST$7.80 +0.02 (+0.26%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$7.81 +0.01 (+0.12%) As of 08/1/2025 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.Tandem Diabetes Care NASDAQ:TNDM$15.40 -0.18 (-1.16%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$15.69 +0.29 (+1.88%) As of 08/1/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
